Pharmala Biotech Holdings Inc.
MDMA
CNSX
| 02/28/2025 | 11/30/2024 | 08/31/2024 | 05/31/2024 | 02/29/2024 | |
|---|---|---|---|---|---|
| Net Income | -207.82% | -191.27% | -4.94% | -- | -- |
| Total Depreciation and Amortization | 393.48% | 837.04% | 2,911.11% | -- | -- |
| Total Amortization of Deferred Charges | 23.76% | -5.48% | -36.03% | -- | -- |
| Total Other Non-Cash Items | 2,738.04% | 835.16% | 8,212.33% | -- | -- |
| Change in Net Operating Assets | -652.86% | -1,005.49% | -203.28% | -- | -- |
| Cash from Operations | -60.28% | -76.12% | 5.50% | -- | -- |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -169.81% | 56.64% | 55.88% | -- | -- |
| Cash from Investing | -169.81% | 56.64% | 55.88% | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 984.88% | 207.56% | 335.82% | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 910.19% | 185.97% | 305.58% | -- | -- |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 131.97% | 95.27% | 133.34% | -- | -- |